The pyruvate-lactate flux, kPL, shows promise as a biomarker of cancer presence and aggressiveness, and assessment of kPL in patient-derived cells may be a useful tool to assess treatment response for advanced personalized medicine. Here we present a novel experimental protocol for the real-time measurement of pyruvate-lactate metabolic flux in multiple mass-limited cell suspension samples using a single dissolution, thereby increasing efficiency and providing greater control of the methodological variability associated with HP experiments. We then applied this protocol to the measurement of pyruvate-lactate flux in melanoma cells for the assessment of treatment response to BRAF inhibition.
This abstract and the presentation materials are available to members only; a login is required.